Search Result

Results for "

cannabinoid acid

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Cannabinoid Receptor (152) Fatty Acid Synthase (FASN) (1) 5-HT Receptor (1) Androgen Receptor (1) Apoptosis (1) Autophagy (6) Bacterial (3) Biochemical Assay Reagents (2) Cholinesterase (ChE) (1) Cytochrome P450 (2) DAGL (2) Dopamine Receptor (1) Endogenous Metabolite (21) FAAH (3) FABP (1) Fungal (1) GPR55 (3) NF-κB (2) NO Synthase (2) P-glycoprotein (1) PDK-1 (1) Potassium Channel (1) PPAR (1) Tau Protein (1) TRP Channel (9)
By Research Areas:	Cancer (14) Cardiovascular Disease (3) Endocrinology (1) Infection (4) Inflammation/Immunology (29) Metabolic Disease (32) Neurological Disease (105)
Click Chemistry:	Azide (1)

177

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Natural
Products

Recombinant Proteins

Antibodies

Click Chemistry

Targets Recommended: Cannabinoid Receptor Amino acid Transporter Amino Acid Derivatives Hydroxycarboxylic Acid Receptor (HCAR) Free Fatty Acid Receptor Fatty Acid Synthase (FASN) Apical Sodium-Dependent Bile Acid Transporter G protein-coupled Bile Acid Receptor 1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-14791A

(±)-Ibipinabant 1 Publications Verification (±)-SLV319; (±)-BMS-646256	Cannabinoid Receptor	Metabolic Disease
(±)-Ibipinabant ((±)-SLV319) is the racemate of SLV319. (±)-Ibipinabant ((±)-SLV319) is a potent and selective cannabinoid-1 (CB-1) receptor antagonist with an IC₅₀ of 22 nM.

HY-10013A

Taranabant racemate MK-0364 racemate	Cannabinoid Receptor	Neurological Disease
Taranabant racemate (MK-0364 racemate) is an antagonist and/or inverse agonist of the *Cannabinoid-1* (CB1) receptor extracted from patent WO 2004048317 A1 .

HY-122799

Cannabigerovarinic acid	Others	Others
Cannabigerovarinic acid is a cannabinoid acid, which is found in Thai Cannabis .

HY-W775306

Cannabidivarinic acid CBDVA	Others	Metabolic Disease Inflammation/Immunology
Cannabidivarinic acid (CBDVA), the carboxylic acid precursor of Cannabidivarin(CBDV), is a non-psychoactive cannabinoid found in Cannabis with anti-inflammatory properties .

HY-135882

OMDM-6	TRP Channel Cannabinoid Receptor Endogenous Metabolite	Neurological Disease
OMDM-6 is a hybrid agonist of vanilloid receptor type 1 (VR1, TRPV1) (EC₅₀=75 nM) and cannabinoid receptor type 1 (CB1) (K_i=3.2 μM). OMDM-6 inhibits anandamide cellular uptake (ACU) with a K_i of 7.0 μM .

HY-135881

OMDM-5	TRP Channel Endogenous Metabolite	Neurological Disease
OMDM-5 is a selective inhibitor of anandamide cellular uptake (ACU), with a K_i of 4.8 μM. OMDM-5 is also a potent vanilloid receptor type 1 (VR1, TRPV1) agonist, with an EC₅₀ of 75 nM, and shows weakly active as cannabinoid receptor type 1 (CB1) ligand (K_i=4.9 μM) .

HY-152251

CB2R/FAAH modulator-1	Cannabinoid Receptor FAAH	Inflammation/Immunology
CB2R/FAAH modulator-1 is a cannabinoid type 2 receptor (CB2R) full agonist with K_is of 14.8 nM and 241.3 nM for CB2R and CB1R, respectively. CB2R/FAAH modulator-1 is a fatty acid amide hydrolase (FAAH) inhibitor with an IC₅₀ of 4 μM. CB2R/FAAH modulator-1 decreases pro-inflammatory and increases anti-inflammatory cytokines production .

HY-128040

Virodhamine hydrochloride	Endogenous Metabolite Cannabinoid Receptor	Neurological Disease
Virodhamine (hydrochloride) is a cannabinoid CB1 receptor partial agonist and cannabinoid CB2 receptor full agonist .

HY-134110

N-Methylarachidonamide	Endogenous Metabolite	Metabolic Disease
Anandamide (AEA) is an endogenous cannabinoid that binds to both central cannabinoid (CB1) and peripheral cannabinoid (CB2) receptors. The biological actions of AEA are terminated by cellular uptake and hydrolysis of the amide bond by the enzyme fatty acid amide hydrolase. Arachidonoyl-N-methyl amide is an analog of anandamide that binds to the human central cannabinoid (CB1) receptor with a Ki of 60 nM. It inhibits rat glial gap junction cell-cell communication 100% at a concentration of 50 μM.

HY-134055

Arachidonoyl-N,N-dimethyl amide Arachidonic acid-N,N-dimethyl amide	Cannabinoid Receptor	Metabolic Disease
Anandamide (AEA) is an endogenous cannabinoid that binds to both central cannabinoid (CB1) and peripheral cannabinoid (CB2) receptors. The biological actions of AEA are terminated by cellular uptake and hydrolysis of the amide bond by the enzyme fatty acid amide hydrolase. Arachidonoyl-N,N-dimethyl amide is an analog of anandamide that exhibits weak or no binding to the human central cannabinoid (CB1) receptor (Ki >1 μM). It inhibits rat glial gap junction cell-cell communication 100% at a concentration of 50 μM.

HY-123594

R-2 Methanandamide	Cannabinoid Receptor	Neurological Disease
R-2 Methanandamide (Compound 2) is a *cannabinoid* Anandamide (HY-10863) analog with a K_i of 119 nM for the cannabinoid receptor (K_i is determined using rat brain membranes with PMSF) .

HY-100197

Synaptamide 1 Publications Verification N-Docosahexaenoyl ethanolamine (DHEA); Docosahexaenoyl ethanolamide	Cannabinoid Receptor	Neurological Disease
Synaptamide (Dehydroepiandrosteron; DHEA) is an endogenous metabolite and structural analogue of Anandamide. Synaptamide binds to both the cannabinoid-1 and 2 (CB1 and CB2) cannabinoid receptors and has anti-inflammatory properties. Synaptamide is the first small-molecule endogenous ligand of an adhesion G protein-coupled receptor (aGPCR) .

HY-117139

NESS 0327	Cannabinoid Receptor	Neurological Disease
NESS 0327 is a *cannabinoid* antagonist with high selectivity for the cannabinoid CB1 receptor. NESS 0327 is more than 60,000-fold selective for the CB1 receptor .

HY-118641

Cannabinodiol	Cannabinoid Receptor	Inflammation/Immunology
Cannabinodiol, a cannabinoid analogue, is a phytocannabinoid .

HY-W110493

Divarin 5-Propylbenzene-1,3-diol	Biochemical Assay Reagents	Others
Divarin is a precursor in the synthesis of cannabinoids .

HY-103330

TC-C 14G	Cannabinoid Receptor	Neurological Disease
TC-C 14G (Compd 14g) is a Cannabinoid-1 Receptor (CB1R) inverse agonist, with a K_i of 4 nM and EC₅₀ of 11 nM for HCB1R, respectively .

HY-W754600

BZO-CHMOXIZID CHM-MDA-19	Cannabinoid Receptor	Others
BZO-CHMOXIZID is a Cannabinoid-like analog .

HY-W783639

Bzo-poxizid	Cannabinoid Receptor	Neurological Disease
Bzo-poxizid is a synthetic cannabinoid that is a psychoactive substance .

HY-110016

Docosatetraenylethanolamide DEA	Endogenous Metabolite Cannabinoid Receptor	Neurological Disease
Docosatetraenylethanolamide (DEA) is a cannabinoid receptor 1 (CB1) agonist. Docosatetraenylethanolamide inhibits the specific binding of cannabinoid probe to rat synaptosomal membranes with a K_i value of 34.4 nM. Docosatetraenylethanolamide can be used in the research of nervous system .

HY-P1397

RVD-Hpα	Cannabinoid Receptor	Neurological Disease
RVD-Hpα, an α-hemoglobin-derived peptide containing three additional amino acids, is a *CB1 cannabinoid* receptor** agonist. RVD-Hpα is a positive allosteric modulator of cannabinoid receptor 2 .

HY-121947

1'-Naphthoyl-2-methylindole	Cannabinoid Receptor	Neurological Disease
1'-Naphthoyl-2-methylindole (Compound 88) is a cannabinoid mimetics and an inhibitor for Win 55212-2, that inhibits 34% of [3H]Win 55212-2 binding to cannabinoid receptors at 3 μM .

HY-135267

5-Fluoropentylindole	Others	Others
5-Fluoropentylindole is the base structure for a variety of synthetic cannabinoids .

HY-117091

DDD-028	Others	Neurological Disease Inflammation/Immunology
DDD-028 is a potent non-opioid, non-cannabinoid analgesic which attenuates neuropathic and inflammatory pain without the possible side effects or abuse potential associated with opioid or cannabinoid activities. DDD-028 can be utilized in analgesic research .

HY-133533

O-2050	Cannabinoid Receptor	Neurological Disease
O-2050 is a high affinity cannabinoid CB₁ receptor antagonist with a K_i of 2.5 nM. O-2050 inhibits cannabinoid CB₂ receptor (K_i=0.2 nM). O-2050 can cause locomotor stimulation in mice .

HY-159115

ART26.12	FABP Cannabinoid Receptor	Metabolic Disease
ART26.12 is an orally active FABP5 inhibitor with anti-cannabinoid properties. ART26.12 effectively prevents and alleviates Oxaliplatin (HY-17371)-induced pain through lipid modulation and cannabinoid receptor activation .

HY-W011051

2-Arachidonoylglycerol 1 Publications Verification	Cannabinoid Receptor Endogenous Metabolite	Neurological Disease
2-Arachidonoylglycerol is a second endogenous cannabinoid ligand in the central nervous system.

HY-118656

Cannabicitran	Others	Neurological Disease
Cannabicitran is a cannabinoid. Cannabicitran can decrease intraocular pressure in rabbits .

HY-152270

Pirnabine	Cannabinoid Receptor	Neurological Disease
Pirnabine is a cannabinoid receptor ligand. Pirnabine can be used for the research of glaucoma .

HY-121545

CB-52	Cannabinoid Receptor	Inflammation/Immunology
CB-52 is the ligand and neutral antagonist of *CB2 cannabinoid* receptor** .

HY-121637

IDFP iso-Prdodecylfluorophosphonate	Cannabinoid Receptor	Neurological Disease
IDFP (iso-Prdodecylfluorophosphonate) is a chemical affinity probe for the cannabinoid CB1 receptor .

HY-120423

AM-6538	Cannabinoid Receptor	Neurological Disease
AM6538 is a long-acting, high affinity and pseudo-irreversible cannabinoid (CB) antagonist. AM6538 is a structural analog of rimonabant. AM6538 can be effectively used to evaluate the apparent efficacy of cannabinoid full and partial agonists. AM6538 may be useful in future studies that require temporary reductions in cannabinoid receptor availability . AM-6538 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-150067

CB1R antagonist 1	Cannabinoid Receptor	Metabolic Disease
CB1R Allosteric modulator 5, a selective cannabinoid-1 receptor (CB1R) inverse agonist with an IC₅₀ value of 4.2 μM and EC₅₀ value of ＞10 μM. CB1R Allosteric modulator 5 can be used for the research of metabolic and obesity .

HY-120953

GAT228	Cannabinoid Receptor	Inflammation/Immunology
GAT228, the enantiomer of GAT211, is an allosteric cannabinoid receptor 1 (CB1) ligand .

HY-158747

CBDPA (CRM) Cannabidiphorolic acid	Others	Others
CBDPA (CRM) is a precursor to CBDP, a synthetic plant cannabinoid. CBDPA (CRM) is a standard substance .

HY-130357

15(S)-HETE Ethanolamide	Cannabinoid Receptor	Others
15(S)-HETE Ethanolamide is a cannabinoid analog the CB1 receptor (K_i of 600 nM) .

HY-151105

CBR Agonist-1	Cannabinoid Receptor	Neurological Disease
CBR Agonist-1 (27a-cis) is a cannabinoid receptor (CBR) agonist with the K_i values of 0.18 μM for CB₁R and 1.22 μM for CB₂R. CBR Agonist-1 (27a-cis) can be used in the study of endogenous cannabinoid system-related diseases .

HY-150029

CB1/2 agonist 3	Cannabinoid Receptor	Neurological Disease
CB1/2 agonist 3 (compound 52), a potent non-selective cannabinoid ligand, is a CB1/CB2 (cannabinoid receptor) competitive agonist. CB1/2 agonist 3 acts on hCB1 and hCB2 with K_i values of 5.9 nM and 3.5 nM, respectively .

HY-103336

Tocrifluor 1117 T1117	GPR55 Cannabinoid Receptor	Cardiovascular Disease
Tocrifluor 1117 (T1117), a fluorescent form of the cannabinoid CB1 receptor antagonist AM251 (HY-15443), is a selective fluorescent GPR55 ligand. Tocrifluor 1117 is a potent tool for identifying the cellular location of cannabinoid receptors (including GPR55 in living tissues) (Ex/Em=543/590 nm) .

HY-148176

ANEB-001	Cannabinoid Receptor	Neurological Disease
ANEB-001 is an orally active CB1 inhibitor, can be used to research acute cannabinoid intoxication .

HY-153800

Monlunabant (S)-MRI-1891; INV-202	Cannabinoid Receptor	Neurological Disease
Monlunabant ((S)-MRI-1891) is a solid dispersions compound, as well as a cannabinoid CB1 receptor inhibitor .

HY-120653

CB1 antagonist 5	Cannabinoid Receptor	Neurological Disease
CB1 antagonist 5 (Compound 25) is an antagonist for *CB1 cannabinoid* receptor, with a K_i of 243 nM and an EC₅₀** of 195 nM .

HY-126719

R-1 Methanandamide Phosphate	Others	Neurological Disease
R-1 Methanandamide Phosphate is a water-soluble prodrug analog of arachidonylethanolamide (AEA). AEA is an endogenous cannabinoid compound .

HY-100328

CB2R-IN-1	Cannabinoid Receptor	Neurological Disease
CB2R-IN-1 is a potent cannabinoid CB₂ receptor inverse agonist with a K_i of 0.9 nM.

HY-134615

Mead ethanolamide	Cannabinoid Receptor Endogenous Metabolite	Neurological Disease
Mead ethanolamide is an endogenous cannabinoid receptor agonist with K_d values of 753 nM and 1810 nM against CB1 and CB2, respectively .

HY-114663

FDU-PB-22	Cannabinoid Receptor	Others
FDU-PB-22 is a new synthetic *cannabinoid* that is rapidly metabolized in HLM, with a half-life of 12.4 minutes .

HY-103331

COR170	Cannabinoid Receptor	Neurological Disease Inflammation/Immunology
COR170 (11u) is a selective CB2 inverse-agonist which is a 4-quinolone-3-carboxylic acid derivative with a K_i value of 3.8 nM for CB2 receptor. COR170 can be used for the research of inflammation and neuroprotection .

HY-N0919

Yangonin 1 Publications Verification	Cannabinoid Receptor NF-κB Autophagy	Inflammation/Immunology
Yangonin exhibits affinity for the human recombinant cannabinoid CB1 receptor with an IC₅₀ and a K_i of 1.79 μM and 0.72 μM, respectively.

HY-146134

PGN36	Cannabinoid Receptor	Inflammation/Immunology
PGN36 (Compound 18) is a selective cannabinoid CB₂ receptor (CB₂R) antagonist with a K_i of 0.09 µM .

HY-122153

VSN-16	Cannabinoid Receptor	Cardiovascular Disease Inflammation/Immunology
VSN-16 is a cannabinoid receptor agonist with vasodilatory activity. VSN-16 can be used for the study of multiple sclerosis .

HY-103333

Arvanil N-Vanillylarachidonamide	TRP Channel Cannabinoid Receptor	Neurological Disease
Arvanil is a ligand for vanilloid receptor 1 (VR1) and cannabinoid 1 (CB1). Arvanil can inhibit spasticity, as a potent neuroprotectant .

Cat. No.	Product Name

HY-L006

GPCR/G Protein Compound Library

2,437 compounds

GPCRs are a large family of cell surface receptors that respond to a variety of external signals. Binding of a signaling molecule to a GPCR results in G protein activation, which in turn triggers the production of any number of second messengers. GPCRs play an important role in the human body, and increased understanding of these receptors has greatly affected modern medicine. In fact, researchers estimate that between one-third to one-half of all approved drugs act by binding to GPCRs. GPCRs are a large group of drug targets in drug discovery.

MCE provides a unique collection of 2,437 small molecules targeting GPCRs that can be used in the screening for various GPCRs-related research and drug development projects.

Cat. No.	Product Name	Type

HY-110004

ACEA Arachidonyl-2-chloroethylamide	Cell Assay Reagents
ACEA (short for arachidonyl-2'-chloroacetamide) is a synthetic organic compound that acts as an agonist of the cannabinoid receptor CB1. It is a chemical that affects the endocannabinoid system in the body, which regulates various physiological processes such as appetite, pain perception, mood, and memory .

HY-W127407

Glycerophospho-N-arachidonoyl ethanolamine

Drug Delivery

Glycerophospho-N-Arachidonoyl Ethanolamine is a N-acylated ethanolamines (NAEs). Most NAEs are naturally occurring lipids with diverse biological activities. Different types of NAE can be derived from glycerophosphate-linked precursors through the activity of glycerophosphodiesterase 1 (GDE1). Glycerophosphate-N-Arachidonoyl Ethanolamine is the precursor of Anandamide (AEA), also known as Anandamide. AEA is an endocannabinoid neurotransmitter that binds to central cannabinoid (CB1) and peripheral cannabinoid (CB2) receptors. It inhibits the specific binding of [3H]-HU-243 to synaptosomal membranes with a Ki value of 52 nM compared to 46 nM for δ9-THC.

HY-134438

Hexanoyl coenzyme A trilithium	Enzyme Substrates
Hexanoyl coenzyme A trilithium is a hexanoyl-based medium-chain fatty acyl coenzyme A that is present in all organisms. Hexanoyl coenzyme A trilithium can be used as a precursor for cannabinoid biosynthesis and acts as a competitive inhibitor of medium-chain acyl coenzyme A dehydrogenase (MCAD) .

Cat. No.	Product Name	Target	Research Area

HY-P1091

Hemopressin (human, mouse)	Cannabinoid Receptor	Neurological Disease
Hemopressin is a nonapeptide derived from the α1-chain of hemoglobin, is originally isolated from rat brain homogenates. Hemopressin is orally active, selective and inverse agonist of CB1 cannabinoid receptors. Hemopressin exerts antinociceptive action in inflammatory pain models .

HY-P1090

Hemopressin(rat)	Cannabinoid Receptor	Neurological Disease
Hemopressin(rat) is a nonapeptide derived from the α1-chain of hemoglobin, is originally isolated from rat brain homogenates. Hemopressin(rat) is orally active, selective and inverse agonist of CB1 cannabinoid receptors. Hemopressin(rat) exerts antinociceptive action in inflammatory pain models .

HY-P1397

RVD-Hpα	Cannabinoid Receptor	Neurological Disease
RVD-Hpα, an α-hemoglobin-derived peptide containing three additional amino acids, is a *CB1 cannabinoid* receptor** agonist. RVD-Hpα is a positive allosteric modulator of cannabinoid receptor 2 .

HY-152270

Pirnabine	Cannabinoid Receptor	Neurological Disease
Pirnabine is a cannabinoid receptor ligand. Pirnabine can be used for the research of glaucoma .

HY-P1091A

Hemopressin(human, mouse) TFA	Cannabinoid Receptor	Neurological Disease
Hemopressin TFA is a nonapeptide derived from the α1-chain of hemoglobin, is originally isolated from rat brain homogenates. Hemopressin TFA is orally active, selective and inverse agonist of CB1 cannabinoid receptors. Hemopressin TFA exerts antinociceptive action in inflammatory pain models .

HY-P1090A

Hemopressin(rat) TFA	Cannabinoid Receptor	Neurological Disease
Hemopressin(rat) TFA is a nonapeptide derived from the α1-chain of hemoglobin, is originally isolated from rat brain homogenates. Hemopressin(rat) TFA is orally active, selective and inverse agonist of CB1 cannabinoid receptors. Hemopressin(rat) TFA exerts antinociceptive action in inflammatory pain models .

Species:	Human (4)
Tag:	His (3) Tag Free (1)
Source:	HEK293 (3) E. coli Cell-free (1)

Cat. No.	Compare	Product Name	Species	Source

HY-P700636

	CNR2 Protein-VLP, Human (HEK293) CNR2; cannabinoid receptor 2 (macrophage); cannabinoid receptor 2; CB2	Human	HEK293
	CNR2 Protein-VLP, Human (HEK293) is recommended for animal immunization, ELISA. It is not recommended for receptor-ligand interaction detection and SPR/BLI assay since there are other irrelevant membrane proteins of the host on the VLP envelope, and the receptor-ligand interaction will have strong background interference. High requirements for chips and experimental protocols are needed for SPR/BLI assays. If VLP control is required, it is recommended HY-P702775. May have binding signals with Anti-His antibodies.

HY-P702255

	CNR2 Protein, Human (Cell-Free, His) cannabinoid receptor 2; CX5; CB-2; CB2	Human	E. coli Cell-free
	CNR2 Protein-VLP, a heterotrimeric G protein-coupled receptor, crucially inhibits adenylate cyclase, mediating functions in inflammatory responses, nociceptive transmission, and bone homeostasis. Its modulation of cellular signaling underscores its significance in physiological processes, positioning CNR2 Protein-VLP as a key regulator in inflammatory, sensory mechanisms, and bone equilibrium. CNR2 Protein, Human (Cell-Free, His) is the recombinant human-derived CNR2 protein, expressed by E. coli Cell-free , with N-10*His labeled tag. The total length of CNR2 Protein, Human (Cell-Free, His) is 360 a.a., with molecular weight of 42.5 kDa.

HY-P702793

	CNR2 Protein-VLP, Human (HEK293, His) CNR2; cannabinoid receptor 2 (macrophage); cannabinoid receptor 2; CB2	Human	HEK293
	CNR2 Protein-VLP, Human (HEK293, His) is recommended for animal immunization, ELISA. It is not recommended for receptor-ligand interaction detection and SPR/BLI assay since there are other irrelevant membrane proteins of the host on the VLP envelope, and the receptor-ligand interaction will have strong background interference. High requirements for chips and experimental protocols are needed for SPR/BLI assays. If VLP control is required, it is recommended HY-P701236. Tags can only be detected under denaturing conditions.

HY-P700408

	CNR1 Protein-VLP, Human (HEK293, His) cannabinoid receptor 1 (brain); CNR; cannabinoid receptor 1; CANN6; CB R; CB1; CB1A; CB1K5; central cannabinoid receptor; CB-R; CB1R	Human	HEK293
	CNR1 Protein-VLP, Human (HEK293, His) is recommended for animal immunization, ELISA. It is not recommended for receptor-ligand interaction detection and SPR/BLI assay since there are other irrelevant membrane proteins of the host on the VLP envelope, and the receptor-ligand interaction will have strong background interference. High requirements for chips and experimental protocols are needed for SPR/BLI assays. If VLP control is required, it is recommended HY-P701236. Tags can only be detected under denaturing conditions.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P82605

	*Phospho-Cannabinoid* Receptor I (Ser316) Antibody (YA2350)** CNR1; CNR; cannabinoid receptor 1; CB-R; CB1; CANN6	WB	Human
	Phospho-Cannabinoid Receptor I (Ser316) Antibody (YA2350) is a biotin-conjugated non-conjugated IgG antibody, targeting Phospho-Cannabinoid Receptor I (Ser316), with a predicted molecular weight of 53 kDa (observed band size: 53 kDa). Phospho-Cannabinoid Receptor I (Ser316) Antibody (YA2350) can be used for WB experiment in human background.

HY-P81627

	CB1 Antibody CNR1; CNR; cannabinoid receptor 1; CB-R; CB1; CANN6	WB, IHC-P, IHC-F, ICC/IF, ELISA	Human, Rat
	CB1 Antibody is a rabbit-derived non-conjugated IgG antibody, targeting CB1, with a predicted molecular weight of 52 kDa (observed band size: 52 kDa). CB1 Antibody can be used for WB, IHC-P, IHC-F, ICC/IF, ELISA experiments in human, rat backgrounds.